[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
5-Aug-2014

[ | E-mail ] Share Share

Contact: PLOS Biology
biologypress@plos.org
PLOS

In search for Alzheimer's drug, a major STEP forward

Researchers at Yale School of Medicine have discovered a new drug compound that may help reverse the cognitive deficits of Alzheimer's disease. Their findings are publishing on August 5 in the open access journal PLOS Biology.

The compound, TC-2153, inhibits the negative effects of a protein called STriatal-Enriched tyrosine Phosphatase (STEP), which is key to regulating learning and memory. These cognitive functions are impaired in Alzheimer's.

"Decreasing STEP levels reversed the effects of Alzheimer's disease in mice," said lead author Paul Lombroso, M.D., professor in the Yale Child Study Center and in the Departments of Neurobiology and Psychiatry at Yale School of Medicine.

Lombroso and co-authors studied thousands of small molecules, searching for those that would inhibit STEP activity. Once identified, those STEP-inhibiting compounds were tested in brain cells to examine how effectively they could halt the effects of STEP. They examined the most promising compound in a mouse model of Alzheimer's disease, and found a reversal of deficits in several cognitive exercises that gauged the animals' ability to remember previously seen objects.

High levels of STEP proteins keep synapses in the brain from strengthening. Synaptic strengthening is a process that is required for people to turn short-term memories into long-term memories. When STEP is elevated in the brain, it depletes receptors from synaptic sites, and inactivates other proteins that are necessary for proper cognitive function. This disruption can result in Alzheimer's disease or a number of neuropsychiatric and neurodegenerative disorders, all marked by cognitive deficits.

"The small molecule inhibitor is the result of a five-year collaborative effort to search for STEP inhibitors," said Lombroso. "A single dose of the drug results in improved cognitive function in mice. Animals treated with TC compound were indistinguishable from a control group in several cognitive tasks."

The team is currently testing the TC compound in other animals with cognitive defects, including rats and non-human primates. "These studies will determine whether the compound can improve cognitive deficits in other animal models," said Lombroso. "Successful results will bring us a step closer to testing a drug that improves cognition in humans."

###

Please mention PLOS Biology as the source for this article and include the links below in your coverage to take readers to the online, open access articles

All works published in PLOS Biology are open access, which means that everything is immediately and freely available. Use this URL in your coverage to provide readers access to the paper upon publication: http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1001923

Contact:

Karen N. Peart
Senior Communications Officer
Yale School of Medicine
203-432-1326 or karen.peart@yale.edu

Citation: Xu J, Chatterjee M, Baguley TD, Brouillette J, Kurup P, et al. (2014) Inhibitor of the Tyrosine Phosphatase STEP Reverses Cognitive Deficits in a Mouse Model of Alzheimer's Disease. PLoS Biol 12(8): e1001923. doi:10.1371/journal.pbio.1001923

Funding: The American Health Assistance Foundation (PJL), the Alzheimer's Drug Discovery Foundation (MG, PJL), NIH grants MH091037 and MH52711 (PJL), NS04933901 (GDC and MAG), DA024860 (GMA), MH095532 (LT), GM054051 (JAE), AG047781 (PG), and the Yale/NIDA Neuroproteomics Center (P30 DA018343) funded the work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors declare that they have no competing interests



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.